Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation

Takehiko Mori; Masuho Saburi; Maki Hagihara; Masaaki Mori; Rie Yamazaki; Jun Kato

doi:10.1136/annrheumdis-2020-218695

Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation

Takehiko Mori, Masuho Saburi, Maki Hagihara, Masaaki Mori, Rie Yamazaki, Jun Kato

研究成果: Letter › 査読

本文言語	English
ページ（範囲）	542-543
ページ数	2
ジャーナル	Annals of the rheumatic diseases
巻	80
号	4
DOI	https://doi.org/10.1136/annrheumdis-2020-218695
出版ステータス	Published - 2021 4月 1

ASJC Scopus subject areas

リウマチ学
免疫アレルギー学
免疫学
生化学、遺伝学、分子生物学（全般）

文献へのアクセス

10.1136/annrheumdis-2020-218695

他のファイルとリンク

引用スタイル

@article{a4403587e786432eb2752bdcee7d66e7,

title = "Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation",

keywords = "chondrocytes, cryopyrin-associated periodic syndromes, interleukin 1 receptor antagonist protein",

author = "Takehiko Mori and Masuho Saburi and Maki Hagihara and Masaaki Mori and Rie Yamazaki and Jun Kato",

note = "Funding Information: Competing interests TM received research funding from MSD KK, Novartis Pharma, LSI Medience, Medical & Biological Laboratories, and Asahi Kasei Corporation, and personal fees from Pfizer, MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma, Kyowa Kirin, Chugai Pharmaceutical, Shionogi, Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas Pharma; MM received research funding from Chugai Pharmaceutical, UCB Japan, CSL Behring, Abbvie Japan, Japan Blood Products Organization, Ayumi Pharmaceutical, Nippon Kayaku and Asahi Kasei, personal fees from MSD KK, and consulting fees from Daiichi Sankyo, and Taisho Pharmaceutical.",

year = "2021",

month = apr,

day = "1",

doi = "10.1136/annrheumdis-2020-218695",

language = "English",

volume = "80",

pages = "542--543",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "4",

}

TY - JOUR

T1 - Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation

AU - Mori, Takehiko

AU - Saburi, Masuho

AU - Hagihara, Maki

AU - Mori, Masaaki

AU - Yamazaki, Rie

AU - Kato, Jun

N1 - Funding Information: Competing interests TM received research funding from MSD KK, Novartis Pharma, LSI Medience, Medical & Biological Laboratories, and Asahi Kasei Corporation, and personal fees from Pfizer, MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma, Kyowa Kirin, Chugai Pharmaceutical, Shionogi, Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas Pharma; MM received research funding from Chugai Pharmaceutical, UCB Japan, CSL Behring, Abbvie Japan, Japan Blood Products Organization, Ayumi Pharmaceutical, Nippon Kayaku and Asahi Kasei, personal fees from MSD KK, and consulting fees from Daiichi Sankyo, and Taisho Pharmaceutical.

PY - 2021/4/1

Y1 - 2021/4/1

KW - chondrocytes

KW - cryopyrin-associated periodic syndromes

KW - interleukin 1 receptor antagonist protein

UR - http://www.scopus.com/inward/record.url?scp=85095808572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095808572&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2020-218695

DO - 10.1136/annrheumdis-2020-218695

M3 - Letter

C2 - 33158880

AN - SCOPUS:85095808572

SN - 0003-4967

VL - 80

SP - 542

EP - 543

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

IS - 4

ER -